EN
中文 EN
Our multi-dimensional data solutions accelerate your precision drug development

Cancer genomics guided indication selection

Biomarker discovery for patient stratification

Commercial evaluation for targeted detection

Site selection based on geographic distribution

700000+

Testing Data

600+

Collaborating Hospitals

540+

Publications

20+

Cancer Types

Using BNR's database to explore immune therapy-related biomarkers associated with DDR.
By analyzing the germline mutation status of DDR signaling pathway-related genes across different cancer types, combined with clinical data from immune therapy cohorts, ATM is identified as a potential ICI biomarker
Multi-omics Analysis for Identifying Clinically Relevant Biomarkers
The integration of comprehensive genomic, transcriptomic, proteomic, phosphoproteomic, and microbiome data identified the underlying molecular mechanisms and disease subgroups that were not fully captured by genomic and transcriptomic analysis, and the information may open new paths for the development of personalized targeted therapy and immunotherapy to eventually benefit clinical practice.
We Could Offer More

Genomic Data Solutions

Clinical Trial Solutions

CDx Development & Commercialization

Precision Patient Recruitment
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."